1. Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. Circulation. 2022;145(8):e153-e639. DOI:10.1161/CIR.0000000000001052.
2. Payab M, Abedi M, Foroughi Heravani N et al. Brown adipose tissue transplantation as a novel alternative to obesity treatment: a systematic review. Int J Obes (London). 2021;45(1):109-21. DOI:10.1038/s41366-020-0616-5.
3. Liu C, Han D, Liang P, Li Y, Cao F. The Current Dilemma and Breakthrough of Stem Cell Therapy in Ischemic Heart Disease. Front Cell Dev Biol. 2021;9:636136. DOI:10.3389/fcell.2021.636136.
4. Müller P, Lemcke H, David R. Stem Cell Therapy in Heart Diseases - Cell Types, Mechanisms and Improvement Strategies. Cell Physiol Biochem. 2018;48(6):2607-55. DOI:10.1159/000492704.
5. Chacko L, P Howard J, Rajkumar C, et al. Effects of Percutaneous Coronary Intervention on Death and Myocardial Infarction Stratified by Stable and Unstable Coronary Artery Disease: A Meta-Analysis of Randomized Controlled Trials. Circ Cardiovasc Qual Outcomes. 2020;13(2):e006363. DOI:10.1161/CIRCOUTCOMES.119.006363.
6. Soehnlein O, Libby P. Targeting inflammation in atherosclerosis - from experimental insights to the clinic. Nat Rev Drug Discov. 2021;20(8):589-610. DOI:10.1038/s41573-021-00198-1.
7. Cochain C, Zernecke A. Macrophages in vascular inflammation and atherosclerosis. Pflugers Arch. 2017;469(3-4):485-99. DOI:10.1007/s00424-017-1941-y.
8. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87(6):2095-147. PMID:8630372.
9. IL6R Genetics Consortium Emerging Risk Factors Collaboration; Sarwar N, Butterworth AS, Freitag DFet al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012;379(9822):1205-13. DOI:10.1016/S0140-6736(11)61931-4.
10. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium; Swerdlow DI, Holmes MV, Kuchenbaecker KB, et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012;379(9822):1214-24. DOI:10.1016/S0140-6736(12)60110-X.
11. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404-10. DOI:10.1016/j.jacc.2012.10.027.
12. Ridker PM, Everett BM, Thuren T, et al. CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-31. DOI:10.1056/NEJMoa1707914.
13. Radico F, Zimarino M, Fulgenzi F, et al. Determinants of long-term clinical outcomes in patients with angina but without obstructive coronary artery disease: a systematic review and meta-analysis. Eur Heart J. 2018;39(23):2135-46. DOI 10.1093/eurheartj/ehy185.
14. Jespersen L, Abildstrom SZ, Hvelplund A, et al. Burden of hospital admission and repeat angiography in angina pectoris patients with and without coronary artery disease: a registry-based cohort study. PLoS One. 2014;9(4):e93170. DOI:10.1371/journal.pone.0093170.
15. Shaw LJ, Merz CN, Pepine CJ, et al.; Women's Ischemia Syndrome Evaluation (WISE) Investigators. The economic burden of angina in women with suspected ischemic heart disease: results from the National Institutes of Health--National Heart, Lung, and Blood Institute--sponsored Women's Ischemia Syndrome Evaluation. Circulation. 2006;114(9):894-904. DOI:10.1161/CIRCULATIONAHA.105.609990.
16. Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009;41(4):1149-60. DOI:10.3758/BRM.41.4.1149.
17. Mohammad-Rezaei M, Ahmadi R, Rafiei A, et al. Serum levels of IL-32 in patients with coronary artery disease and its relationship with the serum levels of IL-6 and TNF-α. Mol Biol Rep. 2021;48(5):4263-71. DOI:10.1007/s11033-021-06441-7.
18. Ma W, Shen D, Liu J, et al. Statin Function as an Anti-inflammation Therapy for Depression in Patients With Coronary Artery Disease by Downregulating Interleukin-1β. J Cardiovasc Pharmacol. 2016;67(2):129-35. DOI:10.1097/FJC.0000000000000323.
19. Benjamin EJ, Muntner P, Alonso A, Virani SS, et al.; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019;139(10):e56-e528. DOI:10.1161/CIR.0000000000000659.
20. Koenig W. Inflammation Revisited: Atherosclerosis in The Post-CANTOS Era. Eur Cardiol. 2017;12(2):89-91. DOI:10.15420/ecr.2017:18:1.
21. Musher DM, Abers MS, Corrales-Medina VF. Acute Infection and Myocardial Infarction. N Engl J Med. 2019;380(2):171-6. DOI:10.1056/NEJMra1808137.
22. Sabatine MS, Giugliano RP, Keech AC, et al.; FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-22. DOI:10.1056/NEJMoa1615664.
23. Schuett H, Luchtefeld M, Grothusen C, et al. How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thromb Haemost. 2009;102(2):215-22. DOI:10.1160/TH09-05-0297.
24. Schieffer B, Selle T, Hilfiker A, et al. Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. Circulation. 2004;110(22):3493-500. DOI:10.1161/01.CIR.0000148135.08582.97.
25. Niu W, Liu Y, Qi Y, et al. Association of interleukin-6 circulating levels with coronary artery disease: a meta-analysis implementing mendelian randomization approach. Int J Cardiol. 2012;157(2):243-52. DOI:10.1016/j.ijcard.2011.12.098.
26. Held C, White HD, Stewart RAH, et al.; STABILITY Investigators. Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. J Am Heart Assoc. 2017;6(10):e005077. DOI:10.1161/JAHA.116.005077.
27. Rai H, Colleran R, Cassese S, et al. Association of interleukin 6 -174 G/C polymorphism with coronary artery disease and circulating IL-6 levels: a systematic review and meta-analysis. Inflamm Res. 2021;70(10-12):1075-87. DOI:10.1007/s00011-021-01505-7.
28. Mohammad-Rezaei M, Ahmadi R, Rafiei A, et al. Serum levels of IL-32 in patients with coronary artery disease and its relationship with the serum levels of IL-6 and TNF-α. Mol Biol Rep. 2021;48(5):4263-71. DOI:10.1007/s11033-021-06441-7.
29. Enayati S, Seifirad S, Amiri P, et al. Interleukin-1 beta, interferon-gamma, and tumor necrosis factor-alpha gene expression in peripheral blood mononuclear cells of patients with coronary artery disease. ARYA Atheroscler. 2015;11(5):267-74.